If you've ever sat through a CTMS demo, you've seen the same slide. Site activation tracker. Subject enrollment chart. Monitoring visit calendar. Financial dashboard. The reps say "single source of truth" 14 times and then ask for $80K a year.
The slide isn't wrong. CTMS does those things. But after talking to maybe 60 biotech and small CRO teams over the last year, I've noticed something that doesn't get said in the demo: most clinical trial management software starts working the day your trial is approved, and not a minute earlier.
That's a problem. Here's a primer on what CTMS actually does, who the major vendors are, and the gap I keep watching small biotech teams fall into.
What CTMS does
A Clinical Trial Management System is operational software for running a trial. Think of it as ERP for clinical operations. The core modules:
Study setup. Define the protocol, sites, investigators, milestones, budget. Stand up the trial as a record in the system.
Site management. Track each site through activation: regulatory packages, site initiation visits, contracts, IRB approvals, drug shipment readiness. Most CTMS platforms have a "site status" view that shows which of your 30 sites are stuck on which step.
Subject enrollment. Screen, consent, randomize, track visits. Some CTMS handles enrollment directly; others integrate with an EDC (electronic data capture) for actual data collection.
Monitoring. Plan and track monitoring visits. Capture findings, track follow-ups, generate visit reports. The CRA's home page.
Document management. Versioned protocol, IRB submissions, regulatory binders, training records. eTMF-adjacent. Some CTMS have eTMF built in (Veeva), others integrate.
Finance and grants. Track payments to sites, milestone payments, invoice reconciliation. The least sexy module, the one that makes CFOs sign the contract.
Reporting. Dashboards for sponsors, DSMBs, investors. Enrollment trends, screen failure rates, monitoring findings by site.
That's the job. CTMS is what stops your trial from being run on a 47-tab spreadsheet that one person in your clinical ops team understands.
Who the major vendors are
Rough segmentation of the market as of 2026:
Enterprise (Phase 2/3 sponsors, large CROs):
- Veeva Vault CTMS: the default for big pharma. Tight integration with Veeva eTMF and EDC. $100K+ per year, 3-6 month implementation.
- Medidata (Dassault Systèmes): strong on adaptive trial designs and oncology. Bundle play with Rave EDC.
- Oracle Siebel CTMS: legacy enterprise, still installed at large CROs. Being replaced at most sites with newer platforms.
- IQVIA: full-stack offering, often sold alongside CRO services.
Mid-market (Phase 1/2 sponsors, small CROs):
- RealTime CTMS: site-focused, popular with research sites running multiple sponsors.
- Florence eHub: site-focused with eISF (electronic investigator site file).
- Bio-Optronics Clinical Conductor: solid for academic medical centers.
Site-side / specialized:
- Advarra (formerly Forte OnCore): strong in academic and oncology research networks.
- Clario: formerly ERT, focused on imaging and respiratory endpoints.
- Castor: newer, EDC-first with CTMS modules added on.
This list is not exhaustive. There are 50+ CTMS vendors. Most of them are either thin wrappers around a database, or genuinely good at one slice of the workflow and average at the rest. Picking one is mostly about your trial complexity, your CRO's preference, and which integrations you actually need.
What CTMS doesn't do
Here's the part the sales deck skips.
CTMS assumes you have an approved IND. It assumes the regulatory work is done. It is built to manage the trial that the FDA already cleared.
That assumption breaks for a specific kind of customer: small biotech filing their first or second IND, with no internal regulatory department, working with consultants, trying to get to first-in-human as fast as possible. Those teams don't need site management software yet. They need to know whether their preclinical package is going to hold up at FDA.
The gap looks like this:
- The CTMS doesn't check whether Repeat-Dose Toxicity studies cover the planned dosing duration.
- The CTMS doesn't read the Safety Pharmacology report and flag a non-GLP hERG assay.
- The CTMS doesn't open your Genotoxicity battery and notice the in vivo micronucleus is missing.
- The CTMS doesn't audit your Toxicology Written Summary for whether the MRSD justification is documented well enough for an FDA reviewer to follow.
That's not a knock on CTMS. It's not their job. They're built for the trial, not for the IND that authorizes the trial.
But the practical effect is that small teams buy CTMS too early, expect it to handle "the regulatory side," discover it doesn't, and end up doing manual cross-referencing against ICH M3(R2), S7B, and S2(R1) the same way teams have been doing it for 20 years. PDFs and ctrl+F.
Where this leaves you
If you're running multiple ongoing trials with 10+ sites, you need CTMS. Pick Veeva if you're committed to the Veeva stack, Medidata if you have an oncology focus, or one of the mid-market platforms if you're cost-sensitive. The differences matter, but they're operational, not existential.
If you're filing your first IND and you don't have a trial yet, you don't need CTMS. You need to know whether your preclinical package will pass FDA review. That's a different problem and different software.
That second problem is what we built Regfo for. The rules engine reads your toxicology, pharmacology, and genotoxicity reports, checks them against 24 ICH and FDA guidelines covering 1,054 specific requirements, and tells you which gaps the reviewer is going to flag. With the page number where each gap lives.
It's not a CTMS. It's the layer that sits in front of CTMS — the one that makes sure the trial CTMS will manage actually gets approved in the first place.
Try it on your IND package. Paste the studies, get the gaps in 30 seconds.